For patients with symptomatic and severe tricuspid regurgitation (TR), tricuspid transcatheter edge-to-edge repair (T-TEER) ...

Israeli heart medical device company Innoventric today announced the completion of a $28.5 million Series B financing round.

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. Here’s what the results mean for the ...

The US Investigational Device Exemption study saw patients cease bleeding almost immediately following the procedure needed ...

TTVR also led to "near elimination" of the TR, as 99.1% of people had moderate or less TR (and 95.3% mild or less) at the ...

"We are excited to work with the leading heart valve centers in the U.S. to offer more patients suffering from tricuspid regurgitation a treatment option. The initiation of the TANDEM II Early ...

DUBLIN--(BUSINESS WIRE)--CroíValve, a pioneering medical device company focused on the development of a novel transcatheter device for the treatment of severe+ tricuspid regurgitation (TR ...

New analyses bolster the case for tricuspid TEER and reassure on outcomes in patients with implanted electronic devices.

CroíValve, a pioneering medical device company focused on the development of a novel transcatheter device for the treatment of severe+ tricuspid regurgitation (TR), announced the first patient tr ...

China remains a core market for Edwards Lifesciences, especially with the ongoing improvements in the country's business ...